Related Experiment Video
Updated: Oct 25, 2025
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials:
1Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Abstract:
Four prospective trials have reported apatinib-related efficacy in osteosarcoma, with a high response rate of 43.2%. Currently, Adverse Events (AEs) have increasingly gained attention, as treatment with multiple tyrosine kinase inhibitors (TKIs) is potentially lifelong. For this reason, a consensus meeting of the Chinese Sarcoma Study Group (CSSG), which is a multidisciplinary panel composed of pediatric, medical and surgical oncologists specializing in sarcoma, nurse specialists, oncological senior pharmacists and gastroenterologists, was held to develop comprehensive guidelines on AEs emerging due to apatinib treatment to better assist in the prevention, management, and understanding of AE development. We summarized all AEs that arose in ≥10% of the participants as well as rare AEs that required extra caution to prevent that were observed in these four published prospective trials and arranged these AEs into 14 disorder systems according to CTCAE 5.0. In this review, we discuss strategies for the management of AEs in patients with advanced osteosarcoma, with the aim of maximizing treatment benefits and minimizing the need for apatinib treatment discontinuation. We also focus on providing recommendations for the prophylaxis and treatment of advanced osteosarcoma using apatinib to achieve optimal outcomes.
Insights
Apatinib shows a 43.2% response rate in osteosarcoma. New guidelines from the Chinese Sarcoma Study Group (CSSG) help manage adverse events (AEs) from this tyrosine kinase inhibitor (TKI) treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Apatinib demonstrates significant efficacy in osteosarcoma with a 43.2% response rate.
- Adverse Events (AEs) are a growing concern with long-term tyrosine kinase inhibitor (TKI) therapy for osteosarcoma.
Approach:
- A consensus meeting of the Chinese Sarcoma Study Group (CSSG) developed guidelines for apatinib-related AEs.
- AEs from four prospective trials were summarized and categorized by CTCAE 5.0 into 14 systems.
Key Points:
- Guidelines address prevention and management of common and rare AEs.
- Strategies aim to maximize treatment benefits while minimizing apatinib discontinuation.
- Recommendations cover prophylaxis and treatment for advanced osteosarcoma patients.
Conclusions:
- Comprehensive AE management is crucial for optimizing apatinib therapy in osteosarcoma.
- These guidelines support clinicians in managing patients with advanced osteosarcoma receiving apatinib.
